{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:43:56Z","timestamp":1760359436411,"version":"build-2065373602"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103677","82072664"],"award-info":[{"award-number":["82103677","82072664"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["J202301E034"],"award-info":[{"award-number":["J202301E034"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Patients with alpha-fetoprotein-producing gastric cancer (AFPGC) characterized with elevated serum AFP levels have received increased interest because of their aggressive behavior and poor prognosis. AFPGC patients who are HER2 positive are even poorer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A single-center retrospective real-world analysis was conducted in patients with histologically confirmed gastric cancer, an AFP level\u2009&gt;\u20097\u00a0ng\/ml and who were pathologically HER2 positive at Tianjin Medical University Cancer Institute. Clinical characteristics, treatments and survival were recorded. The last follow-up date was February 10, 2023. The immune microenvironment was detected via multiple immunofluorescence stains.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>From May 2017 to May 2022, 29 advanced patients who were HER2 positive were included in the final analysis of 259 AFPGC patients. The median AFP level was 6745.13\u00a0ng\/ml. Sixteen patients (61.5%) received the quadruplet combination of doublet chemotherapy, trastuzumab and anti-PD-1 antibody. The ORR and DCR were 66.7% and 91.7% in all patients, and 80% and 93.3% in patients in the quadruple combination group. The median progression-free survival (mPFS) and overall survival (mOS) for all patients were 10.27 and 20.50\u00a0months, respectively. For the quadruplet combination group, the mPFS and mOS were 7.47 and 14.87\u00a0months, respectively, but there were still 6 patients without disease progression and 8 patients who were alive (PFS and OS range: 7.3\u201341.07\u00a0months). Multiple immunofluorescence stains revealed significantly fewer CD3\u2009+\u2009, CD8\u2009+\u2009, CD56\u2009+\u2009, and CD68\u2009+\u2009immune cells in the tumor parenchyma and stroma in HER2-positive AFPGC patients than in HER2-negative and AFP-normal gastric cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Compared with current treatments, parts of HER2-positive AFPGC can achieve equivalent ORR and survival benefits, especially with HER2-targeted, anti-PD-1 antibody and chemotherapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14808-3","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T08:24:55Z","timestamp":1760084695000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The combination of anti-PD-1 antibodies, trastuzumab and chemotherapy may improve the outcome of some patients with HER2-positive alpha-fetoprotein-producing gastric cancer: a retrospective real-world analysis from a single center"],"prefix":"10.1186","volume":"25","author":[{"given":"Shaohua","family":"Ge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yansha","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"issue":"1","key":"14808_CR1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","volume":"18","author":"Y Chen","year":"2025","unstructured":"Chen Y, et al. The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis. J Hematol Oncol. 2025;18(1):42.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"14808_CR2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5230\/jgc.2024.24.e7","volume":"24","author":"J Shin","year":"2024","unstructured":"Shin J, Park YS. Unusual or Uncommon Histology of Gastric Cancer. J Gastric Cancer. 2024;24(1):69\u201388.","journal-title":"J Gastric Cancer"},{"key":"14808_CR3","doi-asserted-by":"crossref","first-page":"175883592412556","DOI":"10.1177\/17588359241255628","volume":"17","author":"A Petrillo","year":"2025","unstructured":"Petrillo A, et al. Rare epithelial gastric cancers: a review of the current treatment knowledge. Ther Adv Med Oncol. 2025;17:17588359241255628.","journal-title":"Ther Adv Med Oncol"},{"issue":"5","key":"14808_CR4","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/his.13951","volume":"75","author":"F Castri","year":"2019","unstructured":"Castri F, et al. Gastroblastoma in old age. Histopathology. 2019;75(5):778\u201382.","journal-title":"Histopathology"},{"key":"14808_CR5","volume":"11","author":"XX Kong","year":"2021","unstructured":"Kong XX, et al. The Clinicopathological Characteristics of Alpha-Fetoprotein-Producing Adenocarcinoma of the Gastrointestinal Tract-A Single-Center Retrospective Study. Front Oncol. 2021;11: 635537.","journal-title":"Front Oncol"},{"issue":"1","key":"14808_CR6","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1038\/s41467-021-24170-0","volume":"12","author":"J Lu","year":"2021","unstructured":"Lu J, et al. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. Nat Commun. 2021;12(1):3946.","journal-title":"Nat Commun"},{"key":"14808_CR7","volume":"36","author":"Y Li","year":"2023","unstructured":"Li Y, et al. Characteristics of alpha-fetoprotein-positive gastric cancer revealed by analysis of cancer databases and transcriptome sequencing data. Transl Oncol. 2023;36: 101737.","journal-title":"Transl Oncol"},{"issue":"1","key":"14808_CR8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s12876-021-01986-0","volume":"21","author":"B Wang","year":"2021","unstructured":"Wang B, et al. Both the serum AFP test and AFP\/GPC3\/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma. BMC Gastroenterol. 2021;21(1):408.","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"14808_CR9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00423-023-02817-4","volume":"408","author":"M Akabane","year":"2023","unstructured":"Akabane M, et al. Re-evaluation of the prognosis of alpha-fetoprotein-producing gastric cancer from a single center: a case series study. Langenbecks Arch Surg. 2023;408(1):66.","journal-title":"Langenbecks Arch Surg"},{"issue":"6","key":"14808_CR10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00535-002-1099-y","volume":"38","author":"S Kamei","year":"2003","unstructured":"Kamei S, et al. Evaluation of VEGF and VEGF-C expression in gastric cancer cells producing alpha-fetoprotein. J Gastroenterol. 2003;38(6):540\u20137.","journal-title":"J Gastroenterol"},{"issue":"1","key":"14808_CR11","doi-asserted-by":"crossref","first-page":"20220476","DOI":"10.1515\/biol-2022-0476","volume":"18","author":"X Mao","year":"2023","unstructured":"Mao X, Wang J, Luo F. alpha-Fetoprotein contributes to the malignant biological properties of AFP-producing gastric cancer. Open Life Sci. 2023;18(1):20220476.","journal-title":"Open Life Sci"},{"issue":"4","key":"14808_CR12","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/his.14998","volume":"83","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Exploring the molecular characteristics of the malignant potential of gastric adenocarcinoma with enteroblastic differentiation. Histopathology. 2023;83(4):631\u201346.","journal-title":"Histopathology"},{"issue":"10","key":"14808_CR13","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1002\/cam4.5883","volume":"12","author":"Y Mei","year":"2023","unstructured":"Mei Y, et al. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer. Cancer Med. 2023;12(10):12018\u201333.","journal-title":"Cancer Med"},{"issue":"3","key":"14808_CR14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/jclinpath-2011-200345","volume":"65","author":"G Giuffre","year":"2012","unstructured":"Giuffre G, et al. HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol. 2012;65(3):237\u201341.","journal-title":"J Clin Pathol"},{"issue":"1","key":"14808_CR15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12672-023-00731-1","volume":"14","author":"H Shimizu","year":"2023","unstructured":"Shimizu H, et al. Human epidermal growth factor 2 overexpressed alpha-fetoprotein-producing-gastric cancer. Discov Oncol. 2023;14(1):111.","journal-title":"Discov Oncol"},{"issue":"9742","key":"14808_CR16","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"5","key":"14808_CR17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.21037\/jgo.2016.06.10","volume":"7","author":"CM Kelly","year":"2016","unstructured":"Kelly CM, Janjigian YY. The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyond. J Gastrointest Oncol. 2016;7(5):750\u201362.","journal-title":"J Gastrointest Oncol"},{"key":"14808_CR18","doi-asserted-by":"crossref","unstructured":"Bermudez, A., et al., Her2-Positive and Microsatellite Instability Status in Gastric Cancer-Clinicopathological Implications. Diagnostics (Basel), 2021. 11(6)Process\uff1a944 .","DOI":"10.3390\/diagnostics11060944"},{"key":"14808_CR19","doi-asserted-by":"crossref","unstructured":"Piccioni, S.A., et al., Impact of HER2 and microsatellite instability status on response to neoadjuvant\/conversion therapy and survival in patients with gastric cancer. Eur J Cancer Prev, 2025.","DOI":"10.1097\/CEJ.0000000000000982"},{"key":"14808_CR20","doi-asserted-by":"crossref","unstructured":"Franchina, M., et al., Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes. Int J Mol Sci, 2023. 24(16) :12795.","DOI":"10.3390\/ijms241612795"},{"issue":"1","key":"14808_CR21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.21873\/anticanres.13927","volume":"40","author":"T Kijima","year":"2020","unstructured":"Kijima T, et al. Comparison of HER2 Status Before and After Trastuzumab-based Chemotherapy in Patients With Advanced Gastric Cancer. Anticancer Res. 2020;40(1):75\u201380.","journal-title":"Anticancer Res"},{"issue":"7890","key":"14808_CR22","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727\u201330.","journal-title":"Nature"},{"key":"14808_CR23","doi-asserted-by":"crossref","unstructured":"Strati, A., et al., Targeting the PD-1\/PD-L1 Signaling Pathway for Cancer Therapy: Focus on Biomarkers. Int J Mol Sci, 2025. 26(3) :1235.","DOI":"10.3390\/ijms26031235"},{"issue":"3","key":"14808_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cncy.22224","volume":"128","author":"M Dell'Aquila","year":"2020","unstructured":"Dell\u2019Aquila M, et al. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker. Cancer Cytopathol. 2020;128(3):177\u201389.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"14808_CR25","first-page":"107","volume":"38","author":"H Saito","year":"2018","unstructured":"Saito H, et al. Highly Activated PD-1\/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. Anticancer Res. 2018;38(1):107\u201312.","journal-title":"Anticancer Res"},{"key":"14808_CR26","doi-asserted-by":"crossref","unstructured":"Chen, X.J., et al., Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis. Biomedicines, 2023. 11(7) :2003.","DOI":"10.3390\/biomedicines11072003"},{"issue":"7","key":"14808_CR27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/jclinpath-2017-204928","volume":"71","author":"M Fujimoto","year":"2018","unstructured":"Fujimoto M, et al. HER2 is frequently overexpressed in hepatoid adenocarcinoma and gastric carcinoma with enteroblastic differentiation: a comparison of 35 cases to 334 gastric carcinomas of other histological types. J Clin Pathol. 2018;71(7):600\u20137.","journal-title":"J Clin Pathol"},{"issue":"28","key":"14808_CR28","first-page":"1277","volume":"78","author":"J Bourreille","year":"1970","unstructured":"Bourreille J, et al. Existence of alpha feto protein during gastric-origin secondary cancer of the liver. Presse Med (1893). 1970;78(28):1277\u20138.","journal-title":"Presse Med (1893)"},{"key":"14808_CR29","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/1477-7819-11-246","volume":"11","author":"XD Li","year":"2013","unstructured":"Li XD, et al. Characteristic analysis of alpha-fetoprotein-producing gastric carcinoma in China. World J Surg Oncol. 2013;11:246.","journal-title":"World J Surg Oncol"},{"issue":"2","key":"14808_CR30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.3748\/wjg.v24.i2.266","volume":"24","author":"YK Wang","year":"2018","unstructured":"Wang YK, et al. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP. World J Gastroenterol. 2018;24(2):266\u201373.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"14808_CR31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/ijc.28373","volume":"134","author":"I Thomassen","year":"2014","unstructured":"Thomassen I, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622\u20138.","journal-title":"Int J Cancer"},{"issue":"3","key":"14808_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4251\/wjgo.v9.i3.121","volume":"9","author":"HL Tan","year":"2017","unstructured":"Tan HL, et al. Gastric peritoneal carcinomatosis - a retrospective review. World J Gastrointest Oncol. 2017;9(3):121\u20138.","journal-title":"World J Gastrointest Oncol"},{"key":"14808_CR33","first-page":"117955492211201","volume":"16","author":"X Zhang","year":"2022","unstructured":"Zhang X, et al. The Relationship Between D-dimer and Prognosis in the Patients with Serum Alpha-Fetoprotein-Positive Gastric Cancer: A Retrospective Cohort Study. Clin Med Insights Oncol. 2022;16:11795549221120158.","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"14808_CR34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","volume":"10","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial. Signal Transduct Target Ther. 2025;10(1):100.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"14808_CR35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00262-024-03743-0","volume":"73","author":"T Deng","year":"2024","unstructured":"Deng T, et al. Combinational zimberelimab plus lenvatinib and chemotherapy for alpha-fetoprotein elevated, advanced gastric cancer patients (AFPGC): a phase 1 dose-escalation study. Cancer Immunol Immunother. 2024;73(8):154.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"14808_CR36","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10549-020-05898-7","volume":"184","author":"K Megari","year":"2020","unstructured":"Megari K. Language impairment among patients with different types of cancer Comparison with healthy adults. Breast Cancer Res Treat. 2020;184(3):779\u201382.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"14808_CR37","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/ene.14522","volume":"28","author":"K Megari","year":"2021","unstructured":"Megari K. Instrumental activities of daily living and neuropsychological functioning among patients with different types of cancer. Eur J Neurol. 2021;28(1):66\u201370.","journal-title":"Eur J Neurol"},{"issue":"2","key":"14808_CR38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40211-020-00345-x","volume":"35","author":"K Megari","year":"2021","unstructured":"Megari K. Neuropsychological functioning among patients with different types of cancer\u202f: Postchemotherapy cognitive impairment and implications for rehabilitation. Neuropsychiatr. 2021;35(2):92\u20137.","journal-title":"Neuropsychiatr"},{"key":"14808_CR39","doi-asserted-by":"crossref","first-page":"263310552312209","DOI":"10.1177\/26331055231220906","volume":"19","author":"K Megari","year":"2024","unstructured":"Megari K, et al. What Do Cancer Surgery and orthopedic Surgery Elderly Patients Have in Common? A Long-term Postoperative Cognitive Dysfunction in Orthopedic and Cancer Patients Original Research. Neurosci Insights. 2024;19:26331055231220904.","journal-title":"Neurosci Insights"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14808-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:20:30Z","timestamp":1760358030000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14808-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14808"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14808-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"type":"electronic","value":"1471-2407"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1549"}}